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Abstract 
Background  Multiple endocrine neoplasia type 1 (MEN1) is a genetic disease that predisposes to endocrine 
tumour development. Some cutaneous lesions (angiofibromas, collagenomas, melanosis guttaca, lipomas, 
melanomas, ‘cafe au lait macules’) have been associated to this syndrome. We compare the prevalence of 
cutaneous lesion in affected patients with their non‐carrier relatives.  
Patients and method  We studied 9 patients with MEN1 and 20 non‐carrier, first‐degree relatives. Genetic 
screening was realized in all of them. Patients were examined by dermatologist, and biopsy was performed 
when necessary.  
Results  Patients with MEN1 presented hyperparathyroidism (100%), neuroendocrine tumours of pancreas 
(66%) and pituitary adenomas (44%); their relatives were free of endocrine features of MEN1. The studied 
cutaneous lesions were more prevalent in affected patients than in non‐carriers (55.5% vs. 25%; P = 0.029). 
Odds ratio of developing cutaneous lesions in MEN1 patients was 6.6 (95% confidence interval, 1.09–40.43). 
The frequency of angiofibromas was lower (22.2%) than the reported in other studies (43–88%), and we did 
not find any collagenoma.  
Conclusions  MEN1 is associated to some cutaneous lesions and could be useful for detecting MEN1 carriers 
in an affected family. Cutaneous lesions should be assessed in MEN1 patients.  
Keywords 









Multiple endocrine neoplasia type 1 (MEN1) is an autosomal‐dominant disease that 
predisposes to early, synchronously or metachronously multicentric tumour development in many 
endocrine (mainly parathyroid, pituitary and pancreatic glands) and non‐endocrine organs.1 
 




 and somatic 
mutations have been found in familial and sporadic MEN1 cases; somatic mutations are frequently 
found in sporadic endocrine tumours too.
11
 This gene encodes a 610‐amino acid protein, called 
menin, that acts as a tumour suppressor protein that interacts with a transcription factor (JunD), 
thus decreasing its function.
12
 The inactivation of menin promotes cell replication, tissular 
hyperplasia and tumorigenesis. Diagnosis of MEN1 includes biochemical and radiological 
procedures (Table 1); genetic testing should be performed for carrier identification when two or 
more clinical features are present.
2, 13, 14
 
Table 1. Clinical features and diagnosis of MEN1:2-6 
Mean clinical features  Biochemical assessment  Radiological assessment  
   
Hyperparathyroidism (90%). Calcium, PTH Tc99m sestamibi scan  
Entero‐pancreatic tumours (70%): 
 Gastrinoma (40%) Gastrin, Meal test Computed tomography 
 Non‐functioning Chromogranin A 
 
 Insulinoma Glucose, Insulin, Proinsulin Magnetic resonance imaging 
 PP‐secretor tumour PP. Meal test 
 
 Glucagonoma Glucagon Octreoscan 
 Somatostatinoma Somatostatin 
 
 VIPoma VIP 
 
Pituitary tumours (40%): 
 Prolactinoma (20%) Prolactin Magnetic resonance imaging 
 Non‐functioning 
  
 GH GH, IGF‐1 
 
 Others: ACTH, TSH 
  
Others: 
 Carcinoid tumours Chromogranin A Computed tomography 
Pheochromocitoma Metanephrines Magnetic resonance imaging 
   
 
PTH, parathyroid hormone; GH, growth hormone; IGF‐1, insulin‐like growth factor‐1; ACTH, adrenocorticotropic 
hormone; TSH, thyroid‐stimulating hormone. 
Some endocrine tumour syndromes have characteristic cutaneous manifestations 
(neurofibromas in MEN 2B, ‘cafe au lait macules’ in McCune–Albright syndrome). Ten years ago, 
Darling et al. described the association of some cutaneous lesions as collagenomas, angiofibromas, 
lipomas and ‘cafe au lait macules’ with MEN1.15 The association with angiofibromas was 
confirmed by Sakurai et al.
16
 Recently, collagenomas and angiofibromas have been signaled as 
potential useful markers of MEN1.
17 
 
The aim of this study is to compare the cutaneous manifestations of patients affected by MEN1 
with their relatives that do not carry the mutation.  
  
Patients and methods 
We studied 29 patients (9 with MEN1 and 20 non‐carrier, first‐degree relatives). All patients 
underwent a detailed evaluation to determine the possible presence and extent of MEN1 
involvement. Briefly, this included a review of the personal and family history for MEN1‐related 
symptoms, laboratory studies to assess the possible presence of hormonal overactivity 
(parathyroid, pituitary, pancreas) and imaging studies for possible tumours/adenomas (Table 1). 
Serum hormonal determinations were made by our clinical laboratories. Insulin, growth hormone, 
prolactin and insulin‐like growth factor‐I were measured by a chemiluminescent immunometric 
assay. Parathyroid hormone, gastrin, glucagon and cortisol were measured by radioimmunoassay.  
 
For genetic analysis, DNA was extracted from peripheral blood leucocytes by standard 
procedures. All the coding exons as well as the intron‐exon boundaries of the MEN1 gene were 
polymerase chain reaction (PCR) amplified with pairs of primers and conditions already 
described.
18
 The PCR products were purified and both strands were subjected to cycle sequencing 
using the BigDye terminator kit and run in the 3730 xl DNA Analyser (Applied Biosystems, 
Foster City, CA, USA).  
 
All subjects were examined by a dermatologist to detect skin lesions associated with MEN1 
(angiofibromas, collagenomas, melanosis guttaca, lipomas, melanomas, ‘cafe au lait macules’); 
cutaneous biopsy was made when necessary to confirm the diagnosis.  
 
Quantitative variables are expressed as mean and standard deviation and compared with 
Student's t‐test. Qualitative variables are expressed as percentages and compared with chi‐squared 
test. Fisher correction was used when necessary. Odds Ratio (OR) was calculated with 95% 
confidence interval (95% CI). Statistical significance was accepted as P < 0.05.  
Results 
Patients with MEN1 were 43.4 (9.1) years old, and 55.5% were women. Their relatives were 
37.8 (13.9) years old (P = 0.22), and 55% were men (P = 0.59). Affected patients carried the 
ins360TG (88.9%) or the P12L (11.1%) mutation; carriers of the former were from the same 
kindred. None of these mutations were found in their relatives. All the affected patients had been 
diagnosed of hyperparathyroidism; 66% of them presented neuroendocrine tumours of pancreas 
(40% gastrinomas, 40% insulinomas, 20% somatostatinoma), and 44% presented pituitary 
adenomas (50% microprolactinomas, 50% non‐functioning adenomas). One patient was diagnosed 
of atypical thymic carcinoid. None of the non‐carriers had any endocrine manifestation of MEN1.  
 
Cutaneous lesions, including melanomas and ‘café au lait macules’, were found in 55.5% of 
MEN1 patients and 25% of non‐carriers (P = 0.029). OR was 6.6 (95% CI, 1.09–40.43) for 
cutaneous manifestation in MEN1 patients. The frequency of each cutaneous lesion is summarized 
in Table 2. In MEN1, all lipomas were multiple, and we did not find multiple melanomas. One 
patient presented a melanoma in their right leg, which was surgically treated. The melanoma was 
diagnosed during her usual clinical following of the MEN1 syndrome. She did not present an 
increased number of nevi.  
 
  
Table 2. Frequency of cutaneous lesions. Comparison with other studies 
Cutaneous lesion  
Vidal et al. 
 
Asgharian et al. 
 
Darling et al.  
MEN1 






         
Angiofibroma 22.2% 5%*  64% 8%†  88% 43% 
Collagenoma 0% 0%*  62% 5%†  72% – 
Lipomas 33.3% 10%*  17% 16%*  34% – 
Melanomas 11.1% 0%*  4% 0%*  – – 
Hypomelanosis 11.1% 5%*  – –  6% – 
Macules 0% 10%*  4% 0%*  38% – 
Any cutaneous lesion 55.5% 25%†  – –  – – 
         
 
* Not significant.  
† P < 0.05.  
Discussion 
Classically, MEN1 has been focused in endocrine features, but recent reports have raised the 
interest about other pathologies related to this syndrome. In 1997 was published the first report 
that associated some cutaneous lesions to MEN1, mainly facial angiofibromas and collagenomas.
15
 
These findings were of great interest because multiple facial angiofibromas were previously 
considered pathognomonic of tuberous sclerosis. In MEN1 syndrome, these cutaneous lesions 
develop when a somatic mutation of the MEN1 gene adds to the germline mutation, which leads to 
cellular replication;
19
 a similar mechanism has been described in endocrine tumours
.2 
Mutations of 
this gene have been described in sporadic melanomas,
19, 20 





as well as in sporadic endocrine tumours.
11 
 
In the present study, we compare patients with MEN1 and their non‐carrier relatives. Patients 
with MEN1 presented the classical endocrine manifestations, but not their relatives. The frequency 
of the endocrine characteristics was similar to the expected. We found that the studied cutaneous 
lesions were more frequent in patients with MEN1, although we did not find significant 
differences in each kind of lesion probably due to the small size of the sample. This result is 
consistent with previous studies.
17
 Surprisingly, the prevalence of angiofibromas was lower in our 
patients (22.2%) than the one reported in literature (43–88%),15-17 and we did not find 
collagenomas or ‘café au lait macules’. The small number of studied patients may explain this 
difference. Nevertheless, MEN1 syndrome is characterized by heterogeneity of the clinical 
manifestations, and any relationship between genotype and phenotype has not been established.2, 
23-25
 Burgess et al
.26
 suggested that a second genetic defect could be involved in phenotype 
heterogeneity, but this second mutation has not been found. The lower prevalence of 
angiofibromas may be related to this heterogeneity or could be explained by the shared mutation 




 explained the lower frequency of angiofibromas that they found by ethnic 
differences, related to lower frequency of somatic mutations in Japanese people and higher 
incidence of non‐melanoma skin cancer in white population, but this explanation is not applicable 
to our Caucasian patients. Finally, environmental factors (e.g. ultraviolet radiation exposure) 
should be considered.  
  
The combination of multiple angiofibromas and any collagenoma has a high sensitivity (75%) 
and specifity (95%), similar to hyperparathyroidism and gastrinomas, and may be useful for the 
diagnosis of this syndrome.
17
 The findings of our study confirm the elevated risk of some 
cutaneous lesions in MEN1 patients. Although we cannot confirm the conclusions reported by 
Asgharian et al.
17
 due to the small size of the sample, probably the cutaneous lesions may be 
useful for detecting MEN1 carriers in an affected family and should be systematically assessed.  
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